RESUMEN
Vascular calcification (VC), in which vascular smooth muscle cells (VSMCs) undergo differentiation and osteogenic transition, is a common complication of chronic kidney disease (CKD). Recent findings show that nuclear factor-erythroid-2-related factor 2 (NRF2) is an evolutionarily conserved antioxidant and beneficial in preventing vascular senescence and calcification. The roles of NRF2 in the initiation and progression of VC in CKD still need further investigation. CKD-associated VC model rats exhibited significant upregulation of NRF2, NAD(P)H: quinone oxidoreductase-1 (NQO1), osteogenic markers such as alkaline phosphatase (ALP), runt-related transcription factor-2 (RUNX2) and osteopontin (OPN), and ß-catenin compared to CKD rats. Immunohistochemistry further verified these results. In addition, rat aortic VSMCs were isolated and subjected to four treatments: normal control, phosphorus-induced (Pi), Pi + NRF2 activator DMF, and Pi + NRF2 inhibitor ML385. The reactive oxygen species (ROS) generation, malondialdehyde (MDA) content, and calcium deposition of the four treatments were determined. The mRNA and protein expression levels of NRF2, NQO1, and haem oxygenase 1 (HO1) and the osteogenic markers ALP, Runx1, OPN, bone morphogenetic protein 2 (BMP2), and ß-catenin were quantified by RT-PCR and western blotting. VSMC apoptosis was calculated by flow cytometry. The in vitro results suggested that intracellular oxidative stress and calcification were closely associated with NRF2 activity and that the activation of NRF2 could significantly suppress osteogenic transition and apoptosis in VSMCs. Thus, this study indicated that the NRF2-related antioxidant pathway can positively respond to and protect against the initiation and progression of VC in CKD by reducing oxidative stress. This study may contribute insights facilitating the application of the NRF2 antioxidative system as a therapeutic treatment for vascular diseases such as CKD.
Asunto(s)
Antioxidantes/metabolismo , Aorta/metabolismo , Músculo Liso Vascular/metabolismo , Miocitos del Músculo Liso/metabolismo , Factor 2 Relacionado con NF-E2/metabolismo , Insuficiencia Renal Crónica/metabolismo , Transducción de Señal , Calcificación Vascular/metabolismo , Animales , Antígenos de Diferenciación/biosíntesis , Modelos Animales de Enfermedad , Hemo Oxigenasa (Desciclizante)/biosíntesis , Masculino , NAD(P)H Deshidrogenasa (Quinona)/biosíntesis , Ratas , Ratas WistarRESUMEN
BACKGROUND: The aim of this study was to investigate the infection and antimicrobial resistance of Ureaplasma urealyticum (U. urealyticum) and Mycoplasma hominis (M. hominis) in patients with genital tract diseases in Jiangsu, China. METHODS: A total of 3,321 patients suspected with genital tract infectious diseases were enrolled in this study from September 2017 to September 2020. The Mycoplasma detection and antimicrobial susceptibility were tested using the commercially available Mycoplasma kit. RESULTS: Among the 3,321 specimens tested, 1,503 (45.3%) were positive for Mycoplasmas, and the proportion of mono-infection of U. urealyticum is highest (79.5%). The overall infection rate has been increasing in the past 3 years. The positive rate in females (68.7%) was higher than in males (25.0%), and the main infection age group was 20 - 39 (81.2%). Besides, U. urealyticum and M. hominis displayed relative lower resistance rates to gatifloxacin, josamycin, minocycline, and doxycycline (6.0%, 6.5%, 3.1%, and 3.2%, respectively). However, the antimicrobial resistance rates to azithromycin, clindamycin, roxithromycin, sparfloxacin, and ofloxacin were relatively high (45.4%, 42.1%, 34.9, 36.0, and 65.5%, respectively). Antimicrobial resistance of U. urealyticum and M. hominis to these 14 drugs have been changing in the past 3 years. CONCLUSIONS: In total, these preliminary data showed the prevalence and antimicrobial resistance status of U. urealyticum and M. hominis in patients suspected with genital tract infectious diseases, which has use for reference on both prevention and treatment of diseases caused by them.
Asunto(s)
Enfermedades Transmisibles , Infecciones por Mycoplasma , Mycoplasma , Infecciones del Sistema Genital , Infecciones por Ureaplasma , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/epidemiología , Mycoplasma hominis , Prevalencia , Infecciones del Sistema Genital/tratamiento farmacológico , Infecciones del Sistema Genital/epidemiología , Infecciones por Ureaplasma/diagnóstico , Infecciones por Ureaplasma/tratamiento farmacológico , Infecciones por Ureaplasma/epidemiología , Ureaplasma urealyticumRESUMEN
BACKGROUND: Diabetic nephropathy (DN) is the major cause of kidney failure, and glomerular podocytes play critical roles in the pathogenesis of DN by maintaining the glomerular structure and filtration barrier. Klotho and Slit-Robo GTP activating protein 2a (SRGAP2a) have been indicated to play protective roles in reducing kidney injury, but whether there is an internal relationship between these two factors is unclear. METHODS: In this study, we cultured differentiated rat podocytes in vitro and measured the SRGAP2a expressions by immunofluorescence staining, quantitative real-time PCR (qRT-PCR) and western blotting, after siRNA-mediated transforming growth factor ß1 (TGF-ß1) silencing, TGF-ß1 overexpression and in the presence of a reactive oxygen species (ROS) inhibitor. And we detected the expressions of SRGAP2a, small mother against decapentaplegic (Smad)2/3, phosphorylated-Smad2/3 (p-Smad2/3), Smad7, and NAD(P)H oxidase 4 (NOX4), ROS levels and podocyte cytoskeletal remodelling under high glucose (HG) and exogenous klotho conditions. In addition, we performed haematoxylin-eosin (HE) staining and immunohistochemistry with diabetic rat models to confirm the in vitro results. RESULTS: The results indicated that SRGAP2a expression was significantly upregulated under siRNA-mediated TGF-ß1 silencing conditions or after adding a ROS inhibitor, but significantly downregulated with TGF-ß1 overexpression, in the presence of HG. The supplementation of exogenous klotho under HG conditions significantly increased the SRGAP2a expression, remodelled the actin cytoskeleton and altered the expressions of Smad2/3, p-Smad2/3, Smad7 and NOX4 and reduced the ROS generation in podocytes. Moreover, klotho administration protected kidney injury in DN rats. CONCLUSIONS: This study indicated that klotho may modulate the expression of SRGAP2a by regulating the ROS and TGF-ß1 signalling pathways and provided theoretical support for klotho protein as a novel therapeutic strategy for treating DN patients.
Asunto(s)
Diabetes Mellitus , Nefropatías Diabéticas , Proteínas Klotho/metabolismo , Podocitos , Animales , Diabetes Mellitus/metabolismo , Nefropatías Diabéticas/patología , Femenino , Guanosina Trifosfato/metabolismo , Guanosina Trifosfato/uso terapéutico , Humanos , Masculino , Podocitos/metabolismo , ARN Interferente Pequeño , Ratas , Especies Reactivas de Oxígeno/metabolismo , Factor de Crecimiento Transformador beta1/metabolismoRESUMEN
Mitochondrial dysfunction causes renal tubular epithelial cell injury and promotes cell apoptosis and renal tubulointerstitial fibrosis (TIF) progression. TNF receptor-associated protein 1 (TRAP1) is a molecular chaperone protein that is localized in mitochondria. It plays an important role in cell apoptosis; however, its functional mechanism in TIF remains unclear. In this study, we observed the effects of TRAP1 in renal tubular epithelial cell mitochondria in mice with unilateral ureteral obstruction and its function in cell apoptosis and TIF. Results show that TRAP1 could protect the mitochondrial structure in renal tubular epithelial cells; maintain the levels of mitochondrial membrane potential, ATP, and mitochondrial DNA copy number; inhibit reactive oxygen species production; stabilize the expression of the mitochondrial inner membrane protein mitofilin; reduce renal tubular epithelial cell apoptosis; and inhibit TIF. These results provide new theoretical foundations for additional understanding of the antifibrotic mechanism of TRAP1 in the kidney.-Chen, J.-F., Wu, Q.-S., Xie, Y.-X., Si, B.-L., Yang, P.-P., Wang, W.-Y., Hua, Q., He, Q. TRAP1 ameliorates renal tubulointerstitial fibrosis in mice with unilateral ureteral obstruction by protecting renal tubular epithelial cell mitochondria.
Asunto(s)
Células Epiteliales/metabolismo , Proteínas HSP90 de Choque Térmico/metabolismo , Túbulos Renales/metabolismo , Mitocondrias/metabolismo , Obstrucción Ureteral/metabolismo , Animales , Células Epiteliales/efectos de los fármacos , Fibrosis/tratamiento farmacológico , Fibrosis/metabolismo , Túbulos Renales/efectos de los fármacos , Túbulos Renales/patología , Masculino , Ratones Endogámicos C57BL , Sustancias Protectoras/farmacología , Especies Reactivas de Oxígeno/metabolismo , Obstrucción Ureteral/patologíaRESUMEN
This study's objective is to evaluate the correlation relationship between Podocalyxin (PCX), an urinary marker of podocytes, urinary albumin-creatinine ratio (ACR) and the predictive value of PCX in the routine screen of early diabetic kidney disease (DKD) among older people. We also aimed to explore its prediction value despite of other metabolic factor and how PCX alters in the predictive power for early stage of diabetic nephropathy. In retrospective, 320 cases of older patients diagnosed with type 2 diabetes mellitus who met both inclusion and exclusion criteria were collected and divided with levels of urinary albumin, that is, normal albuminuria group, microalbuminuria group and healthy group. The correlation coefficient between PCX and ACR, and the odds ratio of PCX were gauged in the study. Area under the receiver operating characteristic (ROC) curve was also calculated. There were 188 patients in the normal group with urine ACR<30mg/g, and 132 patients in the microproteinuria group with urine ACR 30-300mg/g. 132 cases of DKD diagnosed with ACR, among them, 104 cases of DKD were predicted by PCX. The percentage correction value was 78.8%. The following parameters such as gender, age, course of disease, glycated hemoglobin, triglyceride, total cholesterol, BMI, blood pressure, uric acid, and eGFR were used as variables for adjustment to establish the prediction model of urine PCX and ACR. Multiple logistic regression test was carried out to evaluate against the predictive ability of the model. The area under the ROC curve corresponding to the regression model after adjustment is 0.952. Although factors such as the course of disease, HbA1C, UA, and eGFR could influence on the predictive ability of PCX, PCX still has a good ability to predict early DKD in older patients. Therefore, it could be used as a diagnostic indicator for early-stage DKD in older patients.
Asunto(s)
Diabetes Mellitus Tipo 2 , Nefropatías Diabéticas , Humanos , Anciano , Creatinina , Diabetes Mellitus Tipo 2/complicaciones , Estudios Retrospectivos , Albuminuria , AlbúminasRESUMEN
OBJECTIVES: This study was to explore the potential relationship between the fibrinogen-to-albumin ratio (FAR) and the presence and severity of coronary artery disease (CAD) in stage 3-5 predialysis chronic kidney disease (CKD) patients. DESIGN: This study included 978 patients undergoing coronary angiography (CAG). CAD was defined as the presence of obstructive stenosis>50% of the lumen diameter in any of the four main coronary arteries. Gensini scores (GSs), left main coronary artery (LMCA) and three-vessel coronary artery disease (TVD) were used to elevate the severity of CAD. RESULTS: The adjusted odds ratios of CAD were 3.059 (95% CI: 1.859-5.032) and 2.670 (95% CI: 1.605-4.441) in the third and fourth quartiles of FAR compared with the first quartile, respectively. Among 759 patients diagnosed with CAD, multivariate logistic regression analysis showed that FAR (at the 0.01 level) was significantly positively associated with the presence of LMCA (adjusted OR=1.177, 95% CI 1.067-1.299, P=0.001) or TVD (adjusted OR=1.154, 95% CI 1.076-1.238, P<0.001), and a higher GS (adjusted OR=1.152, 95% CI 1.073-1.238, P<0.001). CONCLUSIONS: FAR levels were independently associated with the presence and severity of CAD in stage 3-5 predialysis CKD patients.
Asunto(s)
Enfermedad de la Arteria Coronaria , Fallo Renal Crónico , Insuficiencia Renal Crónica , Humanos , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico por imagen , Angiografía Coronaria , Insuficiencia Renal Crónica/complicaciones , Fallo Renal Crónico/complicaciones , Fibrinógeno , AlbúminasRESUMEN
OBJECTIVE: To investigate the relationship between classification and prognosis of hydronephrosis in fetus. METHODS: 226 pregnant women in their pregnant weeks 20 - 40 who were suggested to be with fetuses suffering from hydronephrosis underwent ultrasonography to observe the configuration of the kidneys, form and size of renal pelvis, extent of calyces, and thickness of renal cortex of their fetuses. The ultrasonography was conducted regularly and the outcome after birth was followed up. RESULTS: 143 fetuses (186 kidneys) were diagnosed as with hydronephrosis of grade I with the anteroposterior diameter of the renal pelvis from 0.3 to 1.1 cm that fadeawayed soon after birth with a good prognosis. 47 fetuses (52 kidneys) were diagnosed as with hydronephrosis of grade II with the anteroposterior diameter of the renal pelvis from 1.0 to 1.8 cm, most of which remised gradually after birth, and only about 5% of which became worse along with the time of pregnancy and needed surgery after birth. 10 fetuses (10 kidneys) were diagnosed as with hydronephrosis of grade III with the anteroposterior diameter of the renal pelvis from 1.5 to 3.3 cm about 70% of which showed a tendency to deteriorate along with the time of pregnancy and after birth, and the neonates needed surgery after birth. Eight fetuses (10 kidneys) were diagnosed as with hydronephrosis of grade IV with the anteroposterior diameter of renal pelvis from 1.5 to 7.2 cm that needed surgery after birth. CONCLUSION: Follow-up and monitoring are not necessary for those fetus with hydronephrosis of grade I; however, regular ultrasonography is needed for the those with hydronephrosis of grade II and over.
Asunto(s)
Enfermedades Fetales/diagnóstico por imagen , Hidronefrosis/diagnóstico por imagen , Ultrasonografía Prenatal , Femenino , Enfermedades Fetales/diagnóstico , Humanos , Hidronefrosis/diagnóstico , Embarazo , Segundo Trimestre del Embarazo , Tercer Trimestre del Embarazo , PronósticoRESUMEN
This study's objective is to evaluate the correlation relationship between Podocalyxin (PCX), an urinary marker of podocytes, urinary albumin-creatinine ratio (ACR) and the predictive value of PCX in the routine screen of early diabetic kidney disease (DKD) among older people. We also aimed to explore its prediction value despite of other metabolic factor and how PCX alters in the predictive power for early stage of diabetic nephropathy. In retrospective, 320 cases of older patients diagnosed with type 2 diabetes mellitus who met both inclusion and exclusion criteria were collected and divided with levels of urinary albumin, that is, normal albuminuria group, microalbuminuria group and healthy group. The correlation coefficient between PCX and ACR, and the odds ratio of PCX were gauged in the study. Area under the receiver operating characteristic (ROC) curve was also calculated. There were 188 patients in the normal group with urine ACR<30mg/g, and 132 patients in the microproteinuria group with urine ACR 30300mg/g. 132 cases of DKD diagnosed with ACR, among them, 104 cases of DKD were predicted by PCX. The percentage correction value was 78.8%. The following parameters such as gender, age, course of disease, glycated hemoglobin, triglyceride, total cholesterol, BMI, blood pressure, uric acid, and eGFR were used as variables for adjustment to establish the prediction model of urine PCX and ACR. Multiple logistic regression test was carried out to evaluate against the predictive ability of the model. The area under the ROC curve corresponding to the regression model after adjustment is 0.952. Although factors such as the course of disease, HbA1C, UA, and eGFR could influence on the predictive ability of PCX, PCX still has a good ability to predict early DKD in older patients. (AU)
El objetivo de este estudio es evaluar la relación de correlación entre la podocalyxina (PCX), un marcador urinario de podocitos, el cociente albúmina-creatinina urinaria (ACR) y el valor predictivo de PCX en el cribado rutinario de la enfermedad renal diabética temprana (ERC) en personas mayores.. También nos propusimos explorar su valor de predicción a pesar de otros factores metabólicos y cómo la PCX altera el poder predictivo de la nefropatía diabética en la etapa temprana. En retrospectiva, se recogieron 320 casos de pacientes mayores diagnosticados con diabetes mellitus tipo 2 que cumplían con los criterios de inclusión y exclusión y se dividieron con los niveles de albúmina urinaria, es decir, grupo de albuminuria normal, grupo de microalbuminuria y grupo sano. El coeficiente de correlación entre PCX y ACR, y la razón de posibilidades de PCX se midió en el estudio. También se calculó el área bajo la curva de característica operativa del receptor (ROC). Hubo 188 pacientes en el grupo normal con ACR en orina <30 mg /gy 132 pacientes en el grupo de microproteinuria con ACR en orina 30-300 mg /g. 132 casos de DKD diagnosticados con ACR, entre ellos 104 casos de DKD fueron predichos por PCX. El valor de corrección porcentual fue del 78,8%. Los siguientes parámetros como sexo, edad, curso de la enfermedad, hemoglobina glucosilada, triglicéridos, colesterol total, IMC, presión arterial, ácido úrico y TFGe se utilizaron como variables de ajuste para establecer el modelo de predicción de PCX y ACR en orina. Se realizó una prueba de regresión logística múltiple para evaluar la capacidad predictiva del modelo. El área bajo la curva ROC correspondiente al modelo de regresión después del ajuste es 0,952. Aunque factores como el curso de la enfermedad, HbA1C, UA y eGFR podrían influir en la capacidad predictiva de PCX, PCX todavía tiene una buena capacidad para predecir la DKD temprana en pacientes mayores. (AU)
Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Albúminas , Enfermedades Renales , Diabetes Mellitus Tipo 2 , Podocitos , Índice de Masa CorporalRESUMEN
Objectives: This study was to explore the potential relationship between the fibrinogen-to-albumin ratio (FAR) and the presence and severity of coronary artery disease (CAD) in stage 35 predialysis chronic kidney disease (CKD) patients.Design: This study included 978 patients undergoing coronary angiography (CAG). CAD was defined as the presence of obstructive stenosis>50% of the lumen diameter in any of the four main coronary arteries. Gensini scores (GSs), left main coronary artery (LMCA) and three-vessel coronary artery disease (TVD) were used to elevate the severity of CAD. Results: The adjusted odds ratios of CAD were 3.059 (95% CI: 1.8595.032) and 2.670 (95% CI: 1.6054.441) in the third and fourth quartiles of FAR compared with the first quartile, respectively. Among 759 patients diagnosed with CAD, multivariate logistic regression analysis showed that FAR (at the 0.01 level) was significantly positively associated with the presence of LMCA (adjusted OR=1.177, 95% CI 1.0671.299, P=0.001) or TVD (adjusted OR=1.154, 95% CI 1.0761.238, P<0.001), and a higher GS (adjusted OR=1.152, 95% CI 1.0731.238, P<0.001). Conclusions: FAR levels were independently associated with the presence and severity of CAD in stage 35 predialysis CKD patients. (AU)
Objetivos: Este estudio pretendía explorar la relación potencial entre la relación fibrinógeno/albúmina (FAR) y la presencia y la gravedad de la enfermedad arterial coronaria (EAC) en pacientes con enfermedad renal crónica (ERC) en estadio 3-5 en la etapa prediálisis. Diseño: Este estudio incluyó a 978 pacientes tratados mediante angiografía coronaria. La EAC se definió como la presencia de estenosis obstructiva > 50% del diámetro de la luz de cualquiera de las 4 arterias coronarias principales. Se utilizaron las puntuaciones de Gensini (GS), la enfermedad de la arteria coronaria izquierda (EACI) y la EAC de 3 vasos (ETV) para evaluar la gravedad de la EAC. Resultados: Los cocientes de posibilidades de EAC fueron 3,059 (IC del 95%: 1,859-5,032) y 2,670 (IC del 95%: 1,605-4,441) en el tercer y el cuarto cuartiles de la FAR en comparación con el primer cuartil, respectivamente. Entre los 759 pacientes diagnosticados de EAC, el análisis de regresión logística de múltiples variables mostró que la FAR (al nivel 0,01) presentaba una asociación positiva significativa con la presencia de EACI (OR ajustada = 1,177, IC del 95%: 1,067-1,299, p = 0,001) o ETV (OR ajustada=1,154, IC del 95%: 1,076-1,238, p < 0,001) y una puntuación GS mayor (OR ajustada = 1,152, IC del 95%: 1,073-1,238, p < 0,001). Conclusiones: Los niveles de FAR se asociaron de manera independiente con la presencia y la gravedad de EAC en los pacientes con ERC en estadio 3-5 en la etapa prediálisis. (AU)